Actively Recruiting
HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan
Led by PharmaEssentia · Updated on 2025-07-30
1200
Participants Needed
6
Research Sites
146 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective observational research to explore the frequency of Human leukocyte antigen A allele 02:01 (HLA\*02:01) and the expression status of New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in cancer patients in Taiwanese population.
CONDITIONS
Official Title
HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand and voluntarily sign an informed consent form
- Adult aged 18 years or older
- Confirmed diagnosis of one of these solid tumors: head and neck squamous cell carcinoma (excluding nasopharyngeal carcinoma), hepatocellular carcinoma, lung squamous cell carcinoma, synovial sarcoma, triple-negative breast cancer, esophageal squamous cell carcinoma, cervical cancer, or ovarian cancer
- Received standard cancer therapies or have advanced tumors without effective standard treatment or refuse additional standard therapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 1 or less
- Body weight of 50 kilograms or more
- Life expectancy of at least 6 months
- Agree to provide tumor sample for NY-ESO-1 immunohistochemistry staining from fresh or archival tissue
You will not qualify if you...
- Known primary immunodeficiency such as Severe Combined Immunodeficiency Disease or AIDS
- Uncontrolled illnesses such as active infection, symptomatic heart failure, unstable angina, unstable arrhythmia, psychiatric illness, or social issues limiting study compliance
- Diagnosis of two or more active cancers (except if previously cured with disease-free period over 6 months and currently only one target tumor)
- Untreated or symptomatic brain metastasis
- History of organ transplant or allogeneic stem cell transplant
- Other conditions not suitable for enrollment, including previous use of any cell therapy, as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Chang Gung Memorial Hospital, Chiayi Branch
Chiayi City, Taiwan, Taiwan
Actively Recruiting
2
Taichung Veterans General Hospital
Taichung, Taiwan, Taiwan, 407219
Actively Recruiting
3
National Cheng Kung University Hospital
Tainan, Taiwan, Taiwan, 704
Actively Recruiting
4
Taipei Veterans General Hospital
Taipei, Taiwan, Taiwan, 11217
Actively Recruiting
5
National Taiwan University Hospital
Taipei, Taiwan, Taiwan
Actively Recruiting
6
Taipei Medical University Hospital
Taipei, Taiwan, Taiwan
Actively Recruiting
Research Team
H
Hsi-Chi Chang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here